{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:10:36Z","timestamp":1779275436349,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Bendamustine is a chemotherapeutic agent combining alkylating activity with purine analogue properties used for a wide range of malignancies including lymphoma. It is not generally associated with cardiac toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>\n                      In this report, we describe 3 cases of patients with marginal zone lymphoma (MZL), diffuse large B-cell lymphomas (DLBCL), and relapsed classic Hodgkin lymphoma (cHL), who developed atrial fibrillation (AF) 1 to 2 days post bendamustine initiation at a dose ranging from 70\u201390 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcomes<\/jats:title>\n                    <jats:p>The patients were managed with bisoprolol\u2009\u00b1\u2009digoxin and anticoagulation. They continue to be in AF and are under routine follow-up by cardiology. The patients\u2019 lymphoma treatment regimens were changed to alternatives except for the last case, in which she was challenged with another subsequent exposure to bendamustine before she passed away.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Old age, hypertension (HTN), diabetes, and ischemic heart disease (IHD) were possible risk factors for AF. However, one of the reported cases is a patient without any known risk factors. Further studies are needed to confirm this observation, to identify patients at risk, and to investigate the underlying mechanisms of bendamustine-induced AF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251369445","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:36:58Z","timestamp":1755499018000},"page":"762-766","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Atrial fibrillation following bendamustine in three lymphoma patients"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1576-6805","authenticated-orcid":false,"given":"Najwa","family":"Al Himali","sequence":"first","affiliation":[{"name":"Sultan Qaboos University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalil","family":"Al Farsi","sequence":"additional","affiliation":[{"name":"Sultan Qaboos University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,8,17]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010006"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/11633140-000000000-00000"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eup300"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201817"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127102"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0276-9"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001182"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S6085"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.842986"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/11205860-000000000-00000"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5591.5591"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02321"},{"key":"e_1_3_2_16_2","article-title":"Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial","volume":"6","author":"Herold M","unstructured":"Herold M, Hoster E, Janssens A, et al. Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial. Hemasphere 2022 Feb 24; 6: e699. Erratum in: Hemasphere. 2022 May 05;6(6):e725. PMID: 35233508; PMCID: PMC8878871.","journal-title":"Hemasphere"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028753"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164047"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2019.04.008"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(25)05108-3"},{"key":"e_1_3_2_21_2","first-page":"218","article-title":"Rituximab-induced polymorphic ventricular tachycardia","volume":"37","author":"Poterucha JT","year":"2010","unstructured":"Poterucha JT, Westberg M, Nerheim P, et al. Rituximab-induced polymorphic ventricular tachycardia. Tex Heart Inst J 2010; 37: 218\u2013220. PMID: 20401299; PMCID: PMC2851419.","journal-title":"Tex Heart Inst J"},{"key":"e_1_3_2_22_2","first-page":"232470962412558","article-title":"An unusual case of delayed-onset rituximab-induced ventricular tachycardia: a case report","volume":"12","author":"Arabyan G","unstructured":"Arabyan G, Hambartzhumian R, Lim AM, et al. An unusual case of delayed-onset rituximab-induced ventricular tachycardia: a case report. J Investig Med High Impact Case Rep 2024 Jan-Dec; 12: 23247096241255813. PMID: 38767122; PMCID: PMC11107307.","journal-title":"J Investig Med High Impact Case Rep"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251369445","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251369445","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251369445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:56:09Z","timestamp":1779274569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251369445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,17]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10781552251369445"],"URL":"https:\/\/doi.org\/10.1177\/10781552251369445","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,17]]}}}